First Header Logo Second Header Logo

Connection

Elizabeth Alli to Female

Back to Details
This is a "connection" page, showing publications Elizabeth Alli has written about Female.
Elizabeth Alli
Connection Strength
0.185
Female
  1. Alli E, Ford JM. BRCA1: Beyond double-strand break repair. DNA Repair (Amst). 2015 Aug; 32:165-171.
    View in: PubMed
    Score: 0.036
  2. Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res. 2014 Nov 01; 74(21):6205-15.
    View in: PubMed
    Score: 0.034
  3. Alli E, Ford JM. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair (Amst). 2012 May 01; 11(5):522-4.
    View in: PubMed
    Score: 0.029
  4. Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011 Jul 19; 11:7.
    View in: PubMed
    Score: 0.028
  5. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007 May; 71(5):1233-40.
    View in: PubMed
    Score: 0.020
  6. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007 Feb 15; 26(7):1003-12.
    View in: PubMed
    Score: 0.020
  7. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013 Nov; 142(2):389-98.
    View in: PubMed
    Score: 0.008
  8. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15; 70(20):7970-80.
    View in: PubMed
    Score: 0.006
  9. Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res. 2002 May; 8(5):1057-64.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.